• SINOMED completed IPO and became a listed company on the Sci-Tech innovation board (STAR Market)of Shanghai stock exchange


  • SINOMED Group completed the Shareholding System transformation and became a joint-stock company
  • SINOMED expanded its overseas organization with operational subsidiaries in Hong Kong, US, Japan and Europe
  • The BASIS study enrollment begins in China. This is the world’s first clinical study comparing intercranial balloon dilation to medical therapy


  • BuMA Supreme becomes the first DES from China to be granted approval for a simultaneous US FDA, Canadian Health Canada, Japanese PMDA and European trial. The PIONEER III study began enrollment of patients in these regions
  • Established the company’s Neurointervention Department and spearheaded the “Intervention without Implantation” hypothesis in the neurological field
  • Formed a Sino-foreign joint venture after company restructuring and financing from Co-Stone Capital, China Securities, CITIC Securities, Tao Capital and LYFE Capital
  • Tytrak®, NC Thonic® and Sleek Prime Balloon Catheters receives CE mark
  • BuMA® DES registered in Brazil and Kazakhstan
  • Tytrak®, NC Thonic® Balloon Catheter registered in Thailand


  • Results of the PANDA III study are published in the Journal of the American College of Cardiology (JACC)
  • Neuro RX® became the first rapid exchange intercranial balloon catheter approved by China CFDA
  • Tytrak® PTCA balloon catheter approved by China CFDA
  • BuMA® DES registered in Indonesia and Thailand
  • Sleek Prime PTCA Balloon Catheter registered in South Korea


  • BuMA Supreme’s clinical study, PIONEER I, began enrollment in the Netherlands, Belgium, Spain and Portugal
  • “Vascular restoration:  Is there a window of opportunity” by Dr. Jianhua Sun, Xiaoran Kang and Tianzhu Li was published in the journal of Medical Hypotheses
  • SINOMED’s Accufit® TMVR was introduced by Prof. Patrick W. Serruys at PCR Innovators Day


  • NC Thonic® Non-compliant PTCA balloon catheter approved by China CFDA


  • SUN Bare Metal Stent received CE mark


  • SINOMED wholly acquired Alchimedics, a French technical company


  • Novel Biodegradable Drug Coating Coronary Stent BuMA® approved by SFDA


  • Sleek PTCA Balloon Catheter received CE mark


  • SINOMED established in China


  • Sleek PTCA Balloon Catheter and SUN Bare Metal Stent approved by China SFDA


  • Beijing Sun Technology Inc. (prior entity of SINOMED) established in China